News

The ten-year collaboration agreement will focus on translational research for innovative therapies for Alzheimer’s and Parkinson’s diseases. The Cambridge-Elan Centre will discover novel compounds capable of altering the

NVA237 is a long-acting muscarinic antagonist (LAMA) used to treat adult patients with chronic obstructive pulmonary disease (COPD). In April 2005, Novartis licensed the drug from Japan’s Sosei

Immunicum’s vaccine is based on using dendritic cells from healthy individuals and can be mass-produced, leading to commercial advantages, the company said. The study will be conducted on

LAPS-rhGH is currently being evaluated under phase II trial in patients with growth hormone deficiency in European countries. According to the company, the orphan drug designation would be

The company has been charged with, by the US Department of Justice, adulteration and mislabeling of its products, besides violation of current Good Manufacturing Practice (cGMP) regulations. ATF

AMR101 is a prescription-grade omega-3 fatty acid, consisting at least 96% ultra pure EPA (icosapent ethyl). The NDA for AMR101 is backed by data from the two Phase

PharmAust is a unit of Epichem that contributed cash to the university to gain an additional 11% in the JV, proactiveinvestors.com.au reported. It is believed that the treatment

The pre-clinical study compared the use of aerosolised IFN-beta against placebo as either a pre-infection protective measure or as a post-infection treatment measure. The study also reported that

According to the company, the new center, , which is worth CHF250m ($271m), will take the responsibility for investigation and development of pharmaceutical formulations for new active ingredients,